                         SEQUENCE LISTING

<110>  BioMarin Pharmaceutical Inc.
       Wendt, et al.
 
<120>  Variants of C-Type Natriuretic Peptide

<130>  30610/43120B

<150>  60/989,497
<151>  2007-11-21

<150>  61/061,488
<151>  2008-06-13

<160>  144   

<170>  PatentIn version 3.5

<210>  1
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide
                                 

<220>
<221>  MISC_FEATURE                
<223>  wtCNP-22

<220>
<221>  DISULFID
<222>  (6)..(22)
<223>  Cysteines in positions 6 and 22 form cyclic domain via disulfide 
       bond

<400>  1

Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  2
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  CNP-17

<400>  2

Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser Met Ser Gly Leu Gly 
1               5                   10                  15      


Cys 
    


<210>  3
<211>  27
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  CNP-27

<400>  3

Gly Ala Asn Lys Lys Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu 
1               5                   10                  15      


Asp Arg Ile Gly Ser Met Ser Gly Leu Gly Cys 
            20                  25          


<210>  4
<211>  53
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  CNP-53

<400>  4

Asp Leu Arg Val Asp Thr Lys Ser Arg Ala Ala Trp Ala Arg Leu Leu 
1               5                   10                  15      


Gln Glu His Pro Asn Ala Arg Lys Tyr Lys Gly Ala Asn Lys Lys Gly 
            20                  25                  30          


Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser Met 
        35                  40                  45              


Ser Gly Leu Gly Cys 
    50              


<210>  5
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Gly is optionally modified with an amino acid sequence derived 
       from a natriuretic polypeptide, a non-natriuretic polypeptide

<220>
<221>  MOD_RES
<222>  (22)..(22)
<223>  Cys is optionally modified with an amino acid sequence derived 
       from a natriuretic polypeptide, a non-natriuretic polypeptide

<400>  5

Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  6
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Gly is modified with a synthetic or natural polymeric group or 
       combination thereof

<220>
<221>  MOD_RES
<222>  (4)..(4)
<223>  Xaa is Lys or a conservative amino acid substitution thereof, any
       natural or unnatural amino acid or peptidomimetic that does not 
       have a reactive primary amine on a side chain, Arg, Gly, 
       6-hydroxy-norleucine, citrulline (Cit), Gln, Glu or Ser

<220>
<221>  MOD_RES
<222>  (10)..(10)
<223>  Xaa is Lys or a conservative amino acid substitution thereof, any
       natural or unnatural amino acid or peptidomimetic that does not 
       have a reactive primary amine on a side chain, Arg, Gly, 
       6-hydroxy-norleucine, citrulline (Cit), Gln, Glu or Ser

<220>
<221>  MOD_RES
<222>  (22)..(22)
<223>  Cys is optionally modified with a synthetic or natural polymeric 
       group or combination thereof

<400>  6

Gly Leu Ser Xaa Gly Cys Phe Gly Leu Xaa Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  7
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide

<400>  7

Gly Ala Asn Lys Lys 
1               5   


<210>  8
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide

<400>  8

Gly Ala Asn Arg Arg 
1               5   


<210>  9
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide

<400>  9

Gly Ala Asn Pro Arg 
1               5   


<210>  10
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide

<400>  10

Gly Ala Asn Gln Gln 
1               5   


<210>  11
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide

<400>  11

Gly Ala Asn Ser Ser 
1               5   


<210>  12
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide

<400>  12

Gly Ala Asn Arg Gln 
1               5   


<210>  13
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide

<400>  13

Gly Ala Asn Arg Met 
1               5   


<210>  14
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide

<400>  14

Gly Ala Asn Arg Thr 
1               5   


<210>  15
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide

<400>  15

Gly Ala Asn Arg Ser 
1               5   


<210>  16
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide

<400>  16

Ala Ala Trp Ala Arg Leu Leu Gln Glu His Pro Asn Ala 
1               5                   10              


<210>  17
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide

<400>  17

Ala Ala Trp Ala Arg Leu Leu Gln Glu His Pro Asn Ala Arg 
1               5                   10                  


<210>  18
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide

<400>  18

Asp Leu Arg Val Asp Thr Lys Ser Arg Ala Ala Trp Ala Arg 
1               5                   10                  


<210>  19
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide

<400>  19

Gln Glu His Pro Asn Ala Arg Lys Tyr Lys Gly Ala Asn Lys Lys 
1               5                   10                  15  


<210>  20
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide

<400>  20

Gln Glu His Pro Asn Ala Arg Lys Tyr Lys Gly Ala Asn Arg Arg 
1               5                   10                  15  


<210>  21
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide

<400>  21

Asp Leu Arg Val Asp Thr Lys Ser Arg Ala Ala Trp Ala Arg Leu Leu 
1               5                   10                  15      


Gln Glu His Pro Asn Ala Arg Lys Tyr Lys Gly Ala Asn Lys Lys 
            20                  25                  30      


<210>  22
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide

<400>  22

Asp Leu Arg Val Asp Thr Lys Ser Arg Ala Ala Trp Ala Arg Leu Leu 
1               5                   10                  15      


Gln Glu His Pro Asn Ala Arg Lys Tyr Lys Gly Ala Asn Arg Arg 
            20                  25                  30      


<210>  23
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide

<400>  23

Ser Leu Arg Arg Ser Ser 
1               5       


<210>  24
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide

<400>  24

Asn Ser Phe Arg Tyr 
1               5   


<210>  25
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide

<400>  25

Ser Pro Lys Met Val Gln Gly Ser Gly 
1               5                   


<210>  26
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide

<400>  26

Met Val Gln Gly Ser Gly 
1               5       


<210>  27
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide

<400>  27

Lys Val Leu Arg Arg Tyr 
1               5       


<210>  28
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide

<400>  28

Lys Val Leu Arg Arg His 
1               5       


<210>  29
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide

<400>  29

Gly Gln His Lys Asp Asp Asn Pro Asn Leu Pro Arg 
1               5                   10          


<210>  30
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide

<400>  30

Gly Val Pro Gln Val Ser Thr Ser Thr 
1               5                   


<210>  31
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide

<400>  31

Gly Glu Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln 
1               5                   10                  15  


<210>  32
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide

<400>  32

Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser 
1               5                   10                  


<210>  33
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Amino acid extention

<400>  33

Gln Glu His Pro Asn Ala Arg Lys Tyr Lys Gly Ala Asn Lys Lys 
1               5                   10                  15  


<210>  34
<211>  37
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  CNP-22 with amino acid extention

<220>
<221>  MISC_FEATURE
<222>  (19)..(19)
<223>  Xaa is Lys or a conservative amino acid substitution thereof, any
       natural or unnatural amino acid, Arg, Gly, 6-hydroxy-norleucine, 
       citrulline (Cit), Gln, Glu or Ser

<220>
<221>  MISC_FEATURE
<222>  (25)..(25)
<223>  Xaa is Lys or a conservative amino acid substitution thereof, any
       natural or unnatural amino acid, Arg, Gly, 6-hydroxy-norleucine, 
       citrulline (Cit), Gln, Glu or Ser

<220>
<221>  MISC_FEATURE
<222>  (37)..(37)
<223>  Cys is optionally modified with a synthetic, natural or 
       combination polymeric group

<400>  34

Gln Glu His Pro Asn Ala Arg Lys Tyr Lys Gly Ala Asn Lys Lys Gly 
1               5                   10                  15      


Leu Ser Xaa Gly Cys Phe Gly Leu Xaa Leu Asp Arg Ile Gly Ser Met 
            20                  25                  30          


Ser Gly Leu Gly Cys 
        35          


<210>  35
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  CNP22 (K4R)

<400>  35

Gly Leu Ser Arg Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  36
<211>  27
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  GANRR-CNP22(K4R) - CNP27(Arg4)

<400>  36

Gly Ala Asn Arg Arg Gly Leu Ser Arg Gly Cys Phe Gly Leu Lys Leu 
1               5                   10                  15      


Asp Arg Ile Gly Ser Met Ser Gly Leu Gly Cys 
            20                  25          


<210>  37
<211>  27
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  GANPR-CNP22(K4R) - CNP27(Pro4) - Analog CI

<400>  37

Gly Ala Asn Pro Arg Gly Leu Ser Arg Gly Cys Phe Gly Leu Lys Leu 
1               5                   10                  15      


Asp Arg Ile Gly Ser Met Ser Gly Leu Gly Cys 
            20                  25          


<210>  38
<211>  24
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  ER-CNP22

<400>  38

Glu Arg Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile 
1               5                   10                  15      


Gly Ser Met Ser Gly Leu Gly Cys 
            20                  


<210>  39
<211>  24
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog BA - ER-CNP22(K4R)

<400>  39

Glu Arg Gly Leu Ser Arg Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile 
1               5                   10                  15      


Gly Ser Met Ser Gly Leu Gly Cys 
            20                  


<210>  40
<211>  23
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  R-CNP22

<400>  40

Arg Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly 
1               5                   10                  15      


Ser Met Ser Gly Leu Gly Cys 
            20              


<210>  41
<211>  23
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog AZ - R-CNP22(K4R)

<400>  41

Arg Gly Leu Ser Arg Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly 
1               5                   10                  15      


Ser Met Ser Gly Leu Gly Cys 
            20              


<210>  42
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  CNP22 (K4R)(K10R)

<400>  42

Gly Leu Ser Arg Gly Cys Phe Gly Leu Arg Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  43
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  CNP-22 (Cys6-Phe7 variable bond)

<220>
<221>  MOD_RES
<222>  (6)..(7)
<223>  Cys6-Phe7 peptide bond (-C(=O)-NH-) replaced with -CH2-NH-

<220>
<221>  MOD_RES
<222>  (6)..(7)
<223>  Cys6-Phe7 peptide bond (-C(=O)-NH-) replaced with -C(=O)-N(R)- 
       where R is methyl, ethyl, n-propyl, isopropyl, cyclopropyl, 
       n-butyl, isobutyl, sec-butyl or tert-butyl

<220>
<221>  MOD_RES
<222>  (6)..(7)
<223>  Cys6-Phe7 peptide bond (-C(=O)-NH-) replaced with -C(=O)-NH-CH2-

<220>
<221>  MOD_RES
<222>  (6)..(7)
<223>  Cys6-Phe7 peptide bond (-C(=O)-NH-) replaced with -CH2-S-

<220>
<221>  MOD_RES
<222>  (6)..(7)
<223>  Cys6-Phe7 peptide bond (-C(=O)-NH-) replaced with -CH2-S(O)n 
       where n is 1 or 2

<220>
<221>  MOD_RES
<222>  (6)..(7)
<223>  Cys6-Phe7 peptide bond (-C(=O)-NH-) replaced with -CH2-CH2-

<220>
<221>  MOD_RES
<222>  (6)..(7)
<223>  Cys6-Phe7 peptide bond (-C(=O)-NH-) replaced with -CH=CH-

<220>
<221>  MOD_RES
<222>  (6)..(7)
<223>  Cys6-Phe7 peptide bond (-C(=O)-NH-) replaced with -C(=O)-CH2-

<220>
<221>  MOD_RES
<222>  (6)..(7)
<223>  Cys6-Phe7 peptide bond (-C(=O)-NH-) replaced with -CH(CN)-NH-

<220>
<221>  MOD_RES
<222>  (6)..(7)
<223>  Cys6-Phe7 peptide bond (-C(=O)-NH-) replaced with -CH(OH)-CH2-

<220>
<221>  MOD_RES
<222>  (6)..(7)
<223>  Cys6-Phe7 peptide bond (-C(=O)-NH-) replaced with -O-C(=O)-NH-

<220>
<221>  MOD_RES
<222>  (6)..(7)
<223>  Cys6-Phe7 peptide bond (-C(=O)-NH-) replaced with NHC(=O)NH-

<400>  43

Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  44
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  Xaa is 3-amino-2-phenylpropionic acid or D-Phe

<400>  44

Gly Leu Ser Lys Gly Cys Xaa Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  45
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  CNP22 - modified Cys6

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  Xaa is Cys, homocysteine, penicillamine, 2-mercaptopropionic 
       acid, or 3-mercaptopropionic acid.

<400>  45

Gly Leu Ser Lys Gly Xaa Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  46
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Gly is optionally modified with a bone or cartilage targeting 
       compound, a biphosphonate, polyAsp, polyGlu, osteopontin, 
       osteocalcin, or sialoprotein peptides, polymers, PEG, 
       carbohydrates, hydrophobic acids, or amino acids

<220>
<221>  MOD_RES
<222>  (4)..(4)
<223>  Xaa is Lys or a conservative amino acid substitution thereof, any
       natural or unnatural amino acid or peptidomimetic that does not 
       have a reactive primary amine on a side chain, Arg, Gly, 
       6-hydroxy-norleucine, citrulline (Cit), Gln, Ser, or Glu

<220>
<221>  MOD_RES
<222>  (6)..(7)
<223>  Xaa is Cys with peptide bond isosteres between positions 6 and 7

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  Xaa is L-Phe, D-Phe, 3-amino-2-phenylpropionic acid, or 
       N-alkylated derivatives of Phe

<220>
<221>  MOD_RES
<222>  (8)..(8)
<223>  Xaa is Gly, tert-butyl-Gly (tBu-Gly), Thr, Ser, Val or Asn

<220>
<221>  MOD_RES
<222>  (9)..(9)
<223>  Xaa is Leu, Ser, Thr or peptide bond isosteres thereof

<220>
<221>  MOD_RES
<222>  (10)..(10)
<223>  Xaa is Lys or a conservative amino acid substitution thereof, any
       natural or unnatural amino acid, Arg, Gly, 6-hydroxy-norleucine, 
       citrulline (Cit), Gln, Ser or Glu

<220>
<221>  MOD_RES
<222>  (11)..(11)
<223>  Xaa is Leu or peptide bond isosteres thereof

<220>
<221>  MOD_RES
<222>  (14)..(14)
<223>  Xaa is Ile, tBu-Gly and peptide bond isosteres thereof

<220>
<221>  MOD_RES
<222>  (17)..(17)
<223>  Xaa is Met, Val, Asn, beta-Cl-Ala, 2-aminobutyric acid (Abu) or 
       2-amino-isobutyric acid (Aib)

<220>
<221>  MOD_RES
<222>  (20)..(20)
<223>  Xaa is Leu, norleucine (Nle), homoleucine (Hleu), Val, 
       tert-butyl-Ala (tBu-Ala), Ser, Thr, Arg or peptide bond isosteres
       thereof

<220>
<221>  MOD_RES
<222>  (22)..(22)
<223>  Cys is optionally modified with a bone or cartilage targeting 
       compound, a bisphosphonate, polyAsp, polyGlu, osteopontin, 
       osteocalcin or sialoprotein peptides, or amino acid sequences 
       derived from non-CNP polypeptides

<400>  46

Gly Leu Ser Xaa Gly Xaa Xaa Xaa Xaa Xaa Xaa Asp Arg Xaa Gly Ser 
1               5                   10                  15      


Xaa Ser Gly Xaa Gly Cys 
            20          


<210>  47
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Gly is optionally modified with a peptide sequence containing one
       to five amino acids from a natriuretic or non-natriuretic 
       polypeptide

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Gly is optionally modified with a peptide sequence containing one
       to five amino acids from a natriuretic or non-natriuretic 
       polypeptide

<220>
<221>  MOD_RES
<222>  (4)..(4)
<223>  Xaa is Lys or a conservative amino acid substitution thereof, any
       natural or unnatural amino acid or peptidomimetic, Arg, 
       6-hydroxy-norleucine, citrulline (Cit), Gln, Ser, or Glu

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  Xaa is Cys or decarboxy Cys

<220>
<221>  MOD_RES
<222>  (6)..(7)
<223>  Peptide bond between positions 6 and 7 may be replaced with 
       -CH2-NH-

<220>
<221>  MOD_RES
<222>  (6)..(7)
<223>  Peptide bond between positions 6 and 7 may be replaced with 
       -C(=O)-N(R)- where R is methyl, ethyl, n-propyl, isopropyl, 
       cyclopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl

<220>
<221>  MOD_RES
<222>  (6)..(7)
<223>  Peptide bond between positions 6 and 7 may be replaced with 
       -C(=O)-NH-CH2-

<220>
<221>  MOD_RES
<222>  (6)..(7)
<223>  Peptide bond between positions 6 and 7 may be replaced with 
       -CH2-S-

<220>
<221>  MOD_RES
<222>  (6)..(7)
<223>  Peptide bond between positions 6 and 7 may be replaced with 
       -CH2-S(O)n where n is 1 or 2

<220>
<221>  MOD_RES
<222>  (6)..(7)
<223>  Peptide bond between positions 6 and 7 may be replaced with 
       -CH2-CH2-

<220>
<221>  MOD_RES
<222>  (6)..(7)
<223>  Peptide bond between positions 6 and 7 may be replaced with 
       -CH=CH-

<220>
<221>  MOD_RES
<222>  (6)..(7)
<223>  Peptide bond between positions 6 and 7 may be replaced with 
       -C(=O)-CH2-

<220>
<221>  MOD_RES
<222>  (6)..(7)
<223>  Peptide bond between positions 6 and 7 may be replaced with 
       -CH(CN)-NH-

<220>
<221>  MOD_RES
<222>  (6)..(7)
<223>  Peptide bond between positions 6 and 7 may be replaced with 
       -CH(OH)-CH2-

<220>
<221>  MOD_RES
<222>  (6)..(7)
<223>  Peptide bond between positions 6 and 7 may be replaced with 
       -O-C(=O)-NH-

<220>
<221>  MOD_RES
<222>  (6)..(7)
<223>  Peptide bond between positions 6 and 7 may be replaced with 
       -NHC(=O)NH-

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  Xaa is L-Phe, D-Phe, 3-amino-2-phenylpropionic acid, or 
       N-alkylated derivatives of Phe

<220>
<221>  MOD_RES
<222>  (8)..(8)
<223>  Xaa is Gly, tert-butyl-Gly (tBu-Gly), Val, Ser, Thr or Asn

<220>
<221>  MOD_RES
<222>  (9)..(9)
<223>  Xaa is Leu, Ser, Thr or peptide bond isosteres thereof

<220>
<221>  MOD_RES
<222>  (10)..(10)
<223>  Xaa is Arg, Gly, 6-hydroxy-norleucine, citrulline (Cit), Gln, Ser
       or Glu

<220>
<221>  MOD_RES
<222>  (11)..(11)
<223>  Xaa is Leu or peptide isosteres thereof

<220>
<221>  MOD_RES
<222>  (14)..(14)
<223>  Xaa is Ile, tBu-Gly or peptide isosteres thereof

<220>
<221>  MOD_RES
<222>  (17)..(17)
<223>  Xaa is Met, Val, Asn, beta-Cl-Ala, 2-aminobutyric acid (Abu) or 
       2-amino-isobutyric acid (Aib)

<220>
<221>  MOD_RES
<222>  (20)..(20)
<223>  Xaa is Leu, norleucine (Nle), homoleucine (Hleu), Val, 
       tert-butyl-Ala (tBu-Ala), Ser, Thr, Arg, or peptide bond 
       isosteres thereof

<220>
<221>  MOD_RES
<222>  (22)..(22)
<223>  Cys is optionally modified with a synthetic bone targeting 
       compound, a bisphosphonate, polyAsp, polyGlu, osteopontin, 
       osteocalcin or sialoprotein peptides, or charged PEG molecules

<400>  47

Gly Leu Ser Xaa Gly Xaa Xaa Xaa Xaa Xaa Xaa Asp Arg Xaa Gly Ser 
1               5                   10                  15      


Xaa Ser Gly Xaa Gly Cys 
            20          


<210>  48
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Xaa is a synthetic or natural polymeric group or combination 
       thereof

<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Xaa is absent or may be one or more amino acids from 
       Gly-Leu-Ser-Lys-Gly and/or substitutions at one or more of these 
       positions

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  Xaa is Lys, a conservative amino acid substitution, any natural 
       or unnatural amino acid or peptidomimetic that does have a 
       reactive primary amine on a side chain

<220>
<221>  MOD_RES
<222>  (19)..(19)
<223>  Cys is optionally modified with a synthetic or natural polymeric 
       group or a combination thereof

<400>  48

Xaa Xaa Cys Phe Gly Leu Xaa Leu Asp Arg Ile Gly Ser Met Ser Gly 
1               5                   10                  15      


Leu Gly Cys 
            


<210>  49
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Xaa is absent or may be a peptide fragment or water soluble 
       polymer

<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Xaa is Cys or peptide bond isosteres thereof

<220>
<221>  MOD_RES
<222>  (3)..(3)
<223>  Xaa is L-Phe, D-Phe, 3-amino-2-phenylpropionic acid or 
       N-alkylated derivatives of Phe

<220>
<221>  MOD_RES
<222>  (4)..(4)
<223>  Xaa is Gly, tert-butyl-Gly (tBu-Gly), Val, Ser, Thr or Asn

<220>
<221>  MOD_RES
<222>  (5)..(5)
<223>  Xaa is Leu, Ser, Thr or N-Me-Leu

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  Xaa is Lys or a conservative amino acid substitution thereof, any
       natural or unnatural amino acid, Arg, Gly, 6-hydroxy-norleucine, 
       citrulline (Cit), Gln, Ser or Glu

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  Xaa is Leu and peptide bond isosteres thereof

<220>
<221>  MOD_RES
<222>  (10)..(10)
<223>  Xaa is Ile, tBu-Gly or peptide bond isosteres thereof

<220>
<221>  MOD_RES
<222>  (13)..(13)
<223>  Xaa is Met, Val, Asn, beta-Cl-Ala, 2-aminobutyric acid (Abu) or 
       2-amino-isobutyric acid (Aib)

<220>
<221>  MOD_RES
<222>  (16)..(16)
<223>  Xaa is Leu, norleucine (Nle), homoleucine (Hleu), Val, 
       tert-butyl-Ala (tBu-Ala), Ser, Thr, Arg or peptide bond isosteres
       thereof

<220>
<221>  MOD_RES
<222>  (18)..(18)
<223>  Cys is optionally modified with amino acid sequences useful in 
       bone/cartilage targeting, polyAsp or polyGlu, osteopontin, 
       osteocalcin, sialoprotein or sequences derived from NPPC or 
       non-CNP polypeptides

<400>  49

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asp Arg Xaa Gly Ser Xaa Ser Gly Xaa 
1               5                   10                  15      


Gly Cys 
        


<210>  50
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Gly is optionally modified with bone targeting compound, moieties
       to reduce renal clearance, charged PEG molecules or hydrophilic 
       polymers

<220>
<221>  MOD_RES
<222>  (4)..(4)
<223>  Xaa is Lys or a conservative amino acid substitution thereof, any
       natural or unnatural amino acid, Arg, Gly, 6-hydroxy-norleucine, 
       citrulline (Cit), Gln, Ser or Glu

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  Xaa is Cys or peptide isosteres between positions 6 and 7

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  Xaa is L-Phe, D-Phe, 3-amino-2-phenylpropionic acid or 
       N-alkylated derivatives of Phe

<220>
<221>  MOD_RES
<222>  (8)..(8)
<223>  Xaa is Gly, tert-butyl-Gly, Thr, Ser, Val or Asn

<220>
<221>  MOD_RES
<222>  (9)..(9)
<223>  Xaa is Leu, Ser, Thr or peptide bond isosteres thereof

<220>
<221>  MOD_RES
<222>  (10)..(10)
<223>  Xaa is Lys or a conservative amino acid substitution thereof, any
       natural or unnatural amino acid, Arg, Gly, 6-hydroxy-norleucine, 
       citrulline (Cit), Gln, Ser or Glu

<220>
<221>  MOD_RES
<222>  (11)..(11)
<223>  Xaa is Leu, Asn or peptide bond isosteres thereof

<220>
<221>  MOD_RES
<222>  (14)..(14)
<223>  Xaa is Ile, tert-butyl-Gly (tBu-Gly), Asn or peptide bond 
       isosteres thereof

<220>
<221>  MOD_RES
<222>  (15)..(15)
<223>  Xaa is Gly, Arg, Ser or Asn

<220>
<221>  MOD_RES
<222>  (17)..(17)
<223>  Xaa is Met, Val, Asn, beta-Cl-Ala, 2-aminobutyric acid (Abu) or 
       2-amino-isobutyric acid (Aib)

<220>
<221>  MOD_RES
<222>  (20)..(20)
<223>  Xaa is Leu, norleucine (Nle), homoleucine (Hleu), Val, 
       tert-butyl-Ala (tBu-Ala), Arg, Thr, Ser or peptide bond isoteres 
       thereof

<220>
<221>  MOD_RES
<222>  (22)..(22)
<223>  Cys is optionally modified with bone targeting compound, moieties
       to reduce renal clearance, charged PEG molecules or hydrophilic 
       polymers

<400>  50

Gly Leu Ser Xaa Gly Xaa Xaa Xaa Xaa Xaa Xaa Asp Arg Xaa Xaa Ser 
1               5                   10                  15      


Xaa Ser Gly Xaa Gly Cys 
            20          


<210>  51
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Xaa is Arg or Glu

<400>  51

Xaa Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  52
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MOD_RES
<222>  (5)..(5)
<223>  Xaa is Arg, Gln or Ser

<400>  52

Gly Leu Ser Lys Xaa Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  53
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MOD_RES
<222>  (15)..(15)
<223>  Xaa is Ser, Asn, Arg, or Cit

<400>  53

Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Xaa Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  54
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MOD_RES
<222>  (19)..(19)
<223>  Xaa is Ser, Arg, or Asn

<400>  54

Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Xaa Leu Gly Cys 
            20          


<210>  55
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MOD_RES
<222>  (21)..(21)
<223>  Xaa is Ser, Thr, or Arg

<400>  55

Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Xaa Cys 
            20          


<210>  56
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog A

<220>
<221>  BINDING
<222>  (6)..(6)
<223>  CH2NH

<400>  56

Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  57
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analogs B

<220>
<221>  BINDING
<222>  (7)..(7)
<223>  Xaa replaced with N-Me-Phe

<400>  57

Gly Leu Ser Lys Gly Cys Xaa Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  58
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog F

<220>
<221>  BINDING
<222>  (8)..(8)
<223>  tBu

<400>  58

Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  59
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog H

<220>
<221>  BINDING
<222>  (7)..(7)
<223>  Xaa is replaced with NHCH2-CH(Phe)CO

<400>  59

Gly Leu Ser Lys Gly Cys Xaa Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  60
<211>  37
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog BL - CNP37

<400>  60

Gln Glu His Pro Asn Ala Arg Lys Tyr Lys Gly Ala Asn Lys Lys Gly 
1               5                   10                  15      


Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser Met 
            20                  25                  30          


Ser Gly Leu Gly Cys 
        35          


<210>  61
<211>  35
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog CA

<400>  61

Ala Ala Trp Ala Arg Leu Leu Gln Glu His Pro Asn Ala Gly Leu Ser 
1               5                   10                  15      


Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser Met Ser Gly 
            20                  25                  30          


Leu Gly Cys 
        35  


<210>  62
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog CB

<400>  62

Ala Ala Trp Ala Arg Leu Leu Gln Glu His Pro Asn Ala Arg Gly Leu 
1               5                   10                  15      


Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser Met Ser 
            20                  25                  30          


Gly Leu Gly Cys 
        35      


<210>  63
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog CC

<400>  63

Asp Leu Arg Val Asp Thr Lys Ser Arg Ala Ala Trp Ala Arg Gly Leu 
1               5                   10                  15      


Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser Met Ser 
            20                  25                  30          


Gly Leu Gly Cys 
        35      


<210>  64
<211>  27
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  GANQQ-CNP22

<400>  64

Gly Ala Asn Gln Gln Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu 
1               5                   10                  15      


Asp Arg Ile Gly Ser Met Ser Gly Leu Gly Cys 
            20                  25          


<210>  65
<211>  27
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  GANRR-CNP22

<400>  65

Gly Ala Asn Arg Arg Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu 
1               5                   10                  15      


Asp Arg Ile Gly Ser Met Ser Gly Leu Gly Cys 
            20                  25          


<210>  66
<211>  27
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  GANPR-CNP22

<400>  66

Gly Ala Asn Pro Arg Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu 
1               5                   10                  15      


Asp Arg Ile Gly Ser Met Ser Gly Leu Gly Cys 
            20                  25          


<210>  67
<211>  27
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  GANSS-CNP22

<400>  67

Gly Ala Asn Ser Ser Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu 
1               5                   10                  15      


Asp Arg Ile Gly Ser Met Ser Gly Leu Gly Cys 
            20                  25          


<210>  68
<211>  32
<212>  PRT
<213>  Artificial Sequene

<220>
<223>  Sythetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog CD

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  N-terminus BNP tail

<220>
<221>  MOD_RES
<222>  (32)..(32)
<223>  N-terminus BNP tail

<400>  68

Ser Pro Lys Met Val Gln Gly Ser Gly Cys Phe Gly Leu Lys Leu Asp 
1               5                   10                  15      


Arg Ile Gly Ser Met Ser Gly Leu Gly Cys Lys Val Leu Arg Arg His 
            20                  25                  30          


<210>  69
<211>  27
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  GANQQ-CNP22(K4R) - Analog CH

<400>  69

Gly Ala Asn Gln Gln Gly Leu Ser Arg Gly Cys Phe Gly Leu Lys Leu 
1               5                   10                  15      


Asp Arg Ile Gly Ser Met Ser Gly Leu Gly Cys 
            20                  25          


<210>  70
<211>  27
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  GANSS-CNP22(K4R) - Analog CG

<400>  70

Gly Ala Asn Ser Ser Gly Leu Ser Arg Gly Cys Phe Gly Leu Lys Leu 
1               5                   10                  15      


Asp Arg Ile Gly Ser Met Ser Gly Leu Gly Cys 
            20                  25          


<210>  71
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog CS

<400>  71

Gly Gln Glu His Pro Asn Ala Arg Lys Tyr Lys Gly Ala Asn Pro Lys 
1               5                   10                  15      


Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
            20                  25                  30          


Met Ser Gly Leu Gly Cys 
        35              


<210>  72
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog CT

<400>  72

Gly Gln Glu His Pro Asn Ala Arg Lys Tyr Lys Gly Ala Asn Gln Lys 
1               5                   10                  15      


Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
            20                  25                  30          


Met Ser Gly Leu Gly Cys 
        35              


<210>  73
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog CU

<400>  73

Gly Gln Glu His Pro Asn Ala Arg Lys Tyr Lys Gly Ala Asn Gln Gln 
1               5                   10                  15      


Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
            20                  25                  30          


Met Ser Gly Leu Gly Cys 
        35              


<210>  74
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog CW

<400>  74

Gly Gln Glu His Pro Asn Ala Arg Lys Tyr Lys Gly Ala Asn Lys Pro 
1               5                   10                  15      


Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
            20                  25                  30          


Met Ser Gly Leu Gly Cys 
        35              


<210>  75
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide

<400>  75

Gly Gln Glu His Pro Asn Ala Arg Lys Tyr Lys Gly Ala Asn Lys Lys 
1               5                   10                  15      


Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
            20                  25                  30          


Met Ser Gly Leu Gly Cys 
        35              


<210>  76
<211>  37
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog CQ

<400>  76

Gly His His Ser His Glu Gln His Pro His Gly Ala Asn Gln Gln Gly 
1               5                   10                  15      


Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser Met 
            20                  25                  30          


Ser Gly Leu Gly Cys 
        35          


<210>  77
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog CR

<400>  77

Gly Ala His His Pro His Glu His Asp Thr His Gly Ala Asn Gln Gln 
1               5                   10                  15      


Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
            20                  25                  30          


Met Ser Gly Leu Gly Cys 
        35              


<210>  78
<211>  37
<212>  PRT
<213>  Artificial Sequencce

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog CX

<400>  78

Gly His His Ser His Glu Gln His Pro His Gly Ala Asn Pro Arg Gly 
1               5                   10                  15      


Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser Met 
            20                  25                  30          


Ser Gly Leu Gly Cys 
        35          


<210>  79
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog CF

<400>  79

Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gly Leu 
1               5                   10                  15      


Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser Met Ser 
            20                  25                  30          


Gly Leu Gly Cys 
        35      


<210>  80
<211>  39
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog CY

<400>  80

Gly Gln His Lys Asp Asp Asn Pro Asn Leu Pro Arg Gly Ala Asn Pro 
1               5                   10                  15      


Arg Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly 
            20                  25                  30          


Ser Met Ser Gly Leu Gly Cys 
        35                  


<210>  81
<211>  37
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog CE

<400>  81

Gly Glu Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Gly 
1               5                   10                  15      


Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser Met 
            20                  25                  30          


Ser Gly Leu Gly Cys 
        35          


<210>  82
<211>  35
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog CZ

<400>  82

Phe Gly Ile Pro Met Asp Arg Ile Gly Arg Asn Pro Arg Gly Leu Ser 
1               5                   10                  15      


Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser Met Ser Gly 
            20                  25                  30          


Leu Gly Cys 
        35  


<210>  83
<211>  40
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog DA

<400>  83

Gly Lys Arg Thr Gly Gln Tyr Lys Leu Gly Ser Lys Thr Gly Pro Gly 
1               5                   10                  15      


Pro Lys Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile 
            20                  25                  30          


Gly Ser Met Ser Gly Leu Gly Cys 
        35                  40  


<210>  84
<211>  37
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog CK

<400>  84

Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Gly Ala Asn Gln Gln Gly 
1               5                   10                  15      


Leu Ser Arg Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser Met 
            20                  25                  30          


Ser Gly Leu Gly Cys 
        35          


<210>  85
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog CL

<400>  85

Gly Val Pro Gln Val Ser Thr Ser Thr Gly Ala Asn Gln Gln Gly Leu 
1               5                   10                  15      


Ser Arg Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser Met Ser 
            20                  25                  30          


Gly Leu Gly Cys 
        35      


<210>  86
<211>  37
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog CM

<400>  86

Gly Gln Pro Ser Ser Ser Ser Gln Ser Thr Gly Ala Asn Gln Gln Gly 
1               5                   10                  15      


Leu Ser Arg Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser Met 
            20                  25                  30          


Ser Gly Leu Gly Cys 
        35          


<210>  87
<211>  37
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog CN

<400>  87

Gly Gln Thr His Ser Ser Gly Thr Gln Ser Gly Ala Asn Gln Gln Gly 
1               5                   10                  15      


Leu Ser Arg Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser Met 
            20                  25                  30          


Ser Gly Leu Gly Cys 
        35          


<210>  88
<211>  37
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog CO

<400>  88

Gly Ser Thr Gly Gln Trp His Ser Glu Ser Gly Ala Asn Gln Gln Gly 
1               5                   10                  15      


Leu Ser Arg Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser Met 
            20                  25                  30          


Ser Gly Leu Gly Cys 
        35          


<210>  89
<211>  37
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog CP

<400>  89

Gly Ser Ser Ser Ser Ser Ser Ser Ser Ser Gly Ala Asn Gln Gln Gly 
1               5                   10                  15      


Leu Ser Arg Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser Met 
            20                  25                  30          


Ser Gly Leu Gly Cys 
        35          


<210>  90
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Gly is optionally modified with bone targeting compound, a 
       bisphosphonates, polyAsp, polyGlu, osteopontin, osteocalcin, or 
       sialoprotein peptides, negatively charged PEG molecules or 
       natural polymers

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  Xaa is Cys or another natural or unnatural amino acid

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  Xaa is Phe or another natural or unnatural amino acid

<220>
<221>  MOD_RES
<222>  (8)..(8)
<223>  Xaa is Gly, a larger natural or unnatural amino acid or 
       peptidomimetic

<220>
<221>  MOD_RES
<222>  (22)..(22)
<223>  Cys is optionally modified with bone targeting compound, a 
       bisphosphonates, polyAsp, polyGlu, osteopontin, osteocalcin, or 
       sialoprotein peptides, negatively charged PEG molecules or 
       natural polymers

<400>  90

Gly Leu Ser Lys Gly Xaa Xaa Xaa Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  91
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog J

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  Xaa is CH2-NH

<220>
<221>  BINDING
<222>  (9)..(9)
<223>  N-Me

<220>
<221>  BINDING
<222>  (20)..(20)
<223>  N-Me

<400>  91

Gly Leu Ser Lys Gly Xaa Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  92
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog K

<220>
<221>  BINDING
<222>  (9)..(9)
<223>  N-Me

<220>
<221>  BINDING
<222>  (20)..(20)
<223>  N-Me

<400>  92

Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  93
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog L

<220>
<221>  BINDING
<222>  (9)..(9)
<223>  N-Me

<220>
<221>  BINDING
<222>  (11)..(11)
<223>  N-Me

<220>
<221>  BINDING
<222>  (20)..(20)
<223>  N-Me

<400>  93

Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  94
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog M

<220>
<221>  BINDING
<222>  (9)..(9)
<223>  N-Me

<220>
<221>  BINDING
<222>  (11)..(11)
<223>  N-Me

<400>  94

Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  95
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog Z

<400>  95

Gly Leu Ser Arg Gly Cys Tyr Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  96
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog AA

<400>  96

Gly Leu Ser Arg Gly Cys Phe Val Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  97
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog AB

<400>  97

Gly Leu Ser Arg Gly Cys Phe Ser Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  98
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog AC

<400>  98

Gly Leu Ser Arg Gly Cys Phe Thr Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  99
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog AD

<400>  99

Gly Leu Ser Arg Gly Cys Phe Gly Thr Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  100
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog AE

<400>  100

Gly Leu Ser Arg Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Arg Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  101
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog AF

<220>
<221>  MOD_RES
<222>  (15)..(15)
<223>  Xaa is Cit

<400>  101

Gly Leu Ser Arg Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Xaa Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  102
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog AG

<400>  102

Gly Leu Ser Arg Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Val Ser Gly Leu Gly Cys 
            20          


<210>  103
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog AJ

<400>  103

Gly Leu Ser Arg Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Val Gly Cys 
            20          


<210>  104
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog AK

<220>
<221>  MOD_RES
<222>  (20)..(20)
<223>  Xaa is tBu-Ala

<400>  104

Gly Leu Ser Arg Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Xaa Gly Cys 
            20          


<210>  105
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog AT

<400>  105

Glu Leu Ser Glu Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  106
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog AV

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  N-terminus modified with pentanoic acid

<400>  106

Glu Leu Ser Glu Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  107
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog AW

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Heptanoic acid modifying N-terminus

<400>  107

Glu Leu Ser Glu Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  108
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog BB

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  N-terminus modified with heptanoic acid

<400>  108

Glu Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  109
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog BC

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  N-terminus modified with pentanoic acid

<400>  109

Glu Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  110
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog BF

<220>
<221>  MOD_RES
<222>  (10)..(10)
<223>  Xaa is Cit

<400>  110

Gly Leu Ser Arg Gly Cys Phe Gly Leu Xaa Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  111
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog BG

<400>  111

Gly Leu Ser Arg Gly Cys Phe Gly Leu Gln Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  112
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog BH

<400>  112

Gly Leu Ser Arg Gly Cys Phe Gly Leu Arg Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  113
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog BJ

<400>  113

Gly Leu Ser Arg Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Asn Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  114
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog BK

<400>  114

Gly Leu Ser Arg Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Ser Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  115
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog N

<220>
<221>  MISC_FEATURE
<222>  (1)..(22)
<223>  All D-amino acids

<400>  115

Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  116
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog BD

<220>
<221>  BINDING
<222>  (9)..(9)
<223>  N-Me

<400>  116

Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  117
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog BN

<220>
<221>  BINDING
<222>  (11)..(11)
<223>  N-Me

<400>  117

Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  118
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog BE

<220>
<221>  BINDING
<222>  (20)..(20)
<223>  N-Me

<400>  118

Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  119
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog V

<220>
<221>  BINDING
<222>  (7)..(7)
<223>  3,4-dichloro

<400>  119

Gly Leu Ser Gly Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  120
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog X

<220>
<221>  BINDING
<222>  (7)..(7)
<223>  3-methyl

<400>  120

Gly Leu Ser Gly Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  121
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog BP

<400>  121

Gly Leu Ser Arg Ser Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  122
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog BO

<400>  122

Gly Leu Ser Arg Arg Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  123
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog P

<400>  123

Gly Leu Ser Gly Gly Cys Phe Gly Leu Arg Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  124
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog BY

<400>  124

Gly Leu Ser Arg Gly Cys Phe Gly Leu Ser Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  125
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog BZ

<400>  125

Gly Leu Ser Arg Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Gln 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  126
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog BX

<400>  126

Gly Leu Ser Arg Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Asn Ser Gly Leu Gly Cys 
            20          


<210>  127
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog BQ

<400>  127

Gly Leu Ser Arg Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Ser Leu Gly Cys 
            20          


<210>  128
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog BR

<400>  128

Gly Leu Ser Arg Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Arg Leu Gly Cys 
            20          


<210>  129
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog BS

<400>  129

Gly Leu Ser Arg Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Arg Gly Cys 
            20          


<210>  130
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog BT

<400>  130

Gly Leu Ser Arg Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Ser Cys 
            20          


<210>  131
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog BU

<400>  131

Gly Leu Ser Arg Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Thr Cys 
            20          


<210>  132
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog BW

<400>  132

Gly Leu Ser Arg Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Arg Cys 
            20          


<210>  133
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog CJ

<400>  133

Arg Ser Ser Cys Phe Gly Gly Arg Ile Asp Arg Ile Gly Ala Cys 
1               5                   10                  15  


<210>  134
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  N-terminal linked to CNP22 by disuccinimidyl glutarate

<400>  134

Gly Leu Ser Arg Gly Cys Phe Gly Leu Arg Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  135
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  N-terminal linked to CNP22 by Bis-PEO5

<400>  135

Gly Leu Ser Arg Gly Cys Phe Gly Leu Arg Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  136
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog E

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  Xaa is D-Phe

<400>  136

Gly Leu Ser Lys Gly Cys Xaa Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  137
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Sythetic Polypeptide


<220>
<221>  MISC_FEATURE
<223>  Analog G

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  Xaa is 3-Cl-Phe

<400>  137

Gly Leu Ser Lys Gly Cys Xaa Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  138
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Xaa comprises one or more amino acids selected from 
       Gly-Leu-Ser-Lys-Gly or substitutions at one or more of these 
       amino acids and further comprises a hydrophilic or water soluable
       polymer

<400>  138

Xaa Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser Met Ser Gly Leu 
1               5                   10                  15      


Gly Cys 
        


<210>  139
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Cys is modified with a natural and/or synthetic polymer

<220>
<221>  MOD_RES
<222>  (17)..(17)
<223>  Cys is modified with a natural and/or synthetic polymer

<400>  139

Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser Met Ser Gly Leu Gly 
1               5                   10                  15      


Cys 
    


<210>  140
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Gly is modified with a natural and/or synthetic polymer

<220>
<221>  MOD_RES
<222>  (22)..(22)
<223>  Cys is modified with a natural and/or synthetic polymer

<400>  140

Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
1               5                   10                  15      


Met Ser Gly Leu Gly Cys 
            20          


<210>  141
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Cys is modified with a natural and/or synthetic polymeric group 
       or combination thereof

<220>
<221>  MOD_RES
<222>  (5)..(5)
<223>  Xaa is Lys or a conservative amino acid substitution thereof, any
       natural or unnatural amino acid, Arg, Gly, 6-hydroxy-norleucine, 
       citrulline (Cit), Gln, Glu or Ser

<220>
<221>  MOD_RES
<222>  (17)..(17)
<223>  Cys is optionally modified with a natural and/or synthetic 
       polymeric group or combination thereof

<400>  141

Cys Phe Gly Leu Xaa Leu Asp Arg Ile Gly Ser Met Ser Gly Leu Gly 
1               5                   10                  15      


Cys 
    


<210>  142
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Xaa is optionally modified with bone- or cartilage-targeting 
       moieties, moieties that reduce renal clearance, hydrophilic 
       polymers, carbohydrates, hydrophobic acids and combinations 
       thereof

<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Xaa is absent or may comprise 1 to 5 amino acids from 
       Gly-Leu-Ser-Lys-Gly, optionally substituted with a natural or 
       unnatural amino acid

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  Xaa is Lys, any natural or unnatural amino acid or peptidomimetic
       that does not have a reactive primary amine on a side chain

<220>
<221>  MOD_RES
<222>  (19)..(19)
<223>  Xaa is optionally modified with bone- or cartilage-targeting 
       moieties, moieties that reduce renal clearance, hydrophilic 
       polymers, carbohydrates, hydrophobic acids and combinations 
       thereof

<400>  142

Xaa Xaa Cys Phe Gly Leu Xaa Leu Asp Arg Ile Gly Ser Met Ser Gly 
1               5                   10                  15      


Leu Gly Cys 
            


<210>  143
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Gly is optionally modified with cartilage or bone targeting 
       compounds, a bisphosphonate, polyAsp, polyGlu, osteopontin 
       peptides, osteocalcin peptides, sialoprotein peptides, charged 
       PEG molecules or hydrophilic polymers

<220>
<221>  MOD_RES
<222>  (4)..(4)
<223>  Xaa is Lys or a conservative amino acid substitution thereof, any
       natural or unnatural amino acid, Arg, Gly, 6-hydroxy-norleucine, 
       citrulline (Cit), Gln, Ser or Glu

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  Xaa is Cys or peptide isosteres between positions 6 and 7

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  Xaa is L-Phe, D-Phe, N-alkylated Phe, or Phe analog

<220>
<221>  MOD_RES
<222>  (8)..(8)
<223>  Xaa is Gly, tert-butyl-Gly, Thr, Ser, Val or Asn

<220>
<221>  MOD_RES
<222>  (9)..(9)
<223>  Xaa is Leu, Ser, Thr or peptide bond isosteres thereof

<220>
<221>  MOD_RES
<222>  (10)..(10)
<223>  Xaa is Lys or a conservative amino acid substitution thereof, any
       natural or unnatural amino acid, Arg, Gly, 6-hydroxy-norleucine, 
       citrulline (Cit), Gln, Ser or Glu

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  misc_feature
<222>  (14)..(14)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  MOD_RES
<222>  (15)..(15)
<223>  Xaa is Gly, Arg, Ser or Asn

<220>
<221>  misc_feature
<222>  (17)..(17)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  MOD_RES
<222>  (20)..(20)
<223>  Xaa is Leu, norleucine (Nle), homoleucine (Hleu), Val, 
       tert-butyl-Ala (tBu-Ala), Arg, Thr, Ser or peptide bond isoteres 
       thereof

<220>
<221>  MOD_RES
<222>  (22)..(22)
<223>  Cys is optionally modified with cartilage or bone targeting 
       compounds, a bisphosphonate, polyAsp, polyGlu, osteopontin 
       peptides, osteocalcin peptides, sialoprotein peptides, charged 
       PEG molecules or hydrophilic polymers

<400>  143

Gly Leu Ser Xaa Gly Xaa Xaa Xaa Xaa Xaa Xaa Asp Arg Xaa Xaa Ser 
1               5                   10                  15      


Xaa Ser Gly Xaa Gly Cys 
            20          


<210>  144
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide

<400>  144

Gly His Lys Ser Glu Val Ala His Arg Phe Lys Gly Ala Asn Lys Lys 
1               5                   10                  15      


Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser 
            20                  25                  30          


Met Ser Gly Leu Gly Cys 
        35              


